Internationally, lung carcinoma is the primary cause of cancer mortality, its growth and spread contributed by multiple genetic alterations.Kras mutation, among these mutations, is a major cause in adenocarcinoma of the lung.For patients with Kras mutation lung carcinoma, precision medicine, including trametinib, dabrafenib, osimertinib, and afatinib, have emerged as promising therapeutic choices.This article aims to explore the function of drugs, including trametinib, dabrafenib, osimertinib, and afatinib, in managing this aggressive form of lung carcinoma, as well as addressing the specific needs related to their use.Kras mutation is a common genetic…
